摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1,4-Dimethyl-2-isopropyl-imidazol | 37455-73-5

中文名称
——
中文别名
——
英文名称
1,4-Dimethyl-2-isopropyl-imidazol
英文别名
2-isopropyl-1,4-dimethyl-1H-imidazole;1,4-Dimethyl-2-propan-2-ylimidazole
1,4-Dimethyl-2-isopropyl-imidazol化学式
CAS
37455-73-5
化学式
C8H14N2
mdl
——
分子量
138.213
InChiKey
CWTPBHHKMWUZIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.62
  • 拓扑面积:
    17.8
  • 氢给体数:
    0
  • 氢受体数:
    1

文献信息

  • [EN] INHIBITORS OF CBL-B AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE CBL-B ET LEURS PROCÉDÉS D'UTILISATION
    申请人:NURIX THERAPEUTICS INC
    公开号:WO2019148005A1
    公开(公告)日:2019-08-01
    Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.
    揭示了用于抑制泛素蛋白酶体途径中的E3酶Cbl-b的化合物、组合物和使用方法。这些化合物、组合物和方法可用于调节免疫系统,治疗适合免疫系统调节的疾病,并用于体内、体外或体外细胞的治疗。
  • HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS
    申请人:NUVATION BIO INC.
    公开号:US20200231570A1
    公开(公告)日:2020-07-23
    Aminopyrazine compounds as modulators of an adenosine receptor are provided. The compounds may find use as therapeutic agents for the treatment of diseases mediated through a G-protein-coupled receptor signaling pathway and may find particular use in oncology.
    提供了氨基吡嗪化合物作为腺苷受体的调节剂。这些化合物可能作为治疗经由G蛋白偶联受体信号通路介导的疾病的治疗剂,并且可能在肿瘤学中发挥特定作用。
  • Novel 6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection
    申请人:HOFFMANN-LA ROCHE INC.
    公开号:US20150031687A1
    公开(公告)日:2015-01-29
    The invention provides novel compounds having the general formula: wherein R 1 , R 2 , R 3 , R 4 and A are as described herein, compositions including the compounds and methods of using the compounds.
    这项发明提供了具有一般式的新化合物:其中R1、R2、R3、R4和A如本文所述,包括该化合物的组合物和使用该化合物的方法。
  • SUBSTITUTED N-HETEROCYCLYL- AND N-HETEROARYL-TETRAHYDROPYRIMIDINONES AND THE SALTS THEREOF, AND THE USE OF SAME AS HERBICIDAL ACTIVE SUBSTANCES
    申请人:Bayer Aktiengesellschaft
    公开号:US20200390100A1
    公开(公告)日:2020-12-17
    The present invention relates to substituted N-heterocyclyl- and N-heteroaryltetrahydropyrimidinones of the general formula (I) or salts thereof, where the radicals in the general formula (I) correspond to the definitions given in the description, and to the use thereof as herbicides, in particular for controlling broad-leaved weeds and/or weed grasses in crops of useful plants and/or as plant growth regulators for influencing the growth of crops of useful plants.
    本发明涉及通式(I)或其盐的取代N-杂环烷基和N-杂芳基四氢嘧啶酮,其中通式(I)中的基团对应于描述中给出的定义,并将其用作除草剂,特别是用于控制作物中的阔叶杂草和/或杂草草,并/或作为植物生长调节剂,以影响作物的生长。
  • NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO
    申请人:DYCK Brian
    公开号:US20110166116A1
    公开(公告)日:2011-07-07
    New compounds are disclosed which have utility in the treatment of a variety of metabolic related conditions in a patient. The compounds of this invention have the structure (I): wherein R 1 , R 2 , R 3 , n, p, q, and Ar are as defined herein, including stereoisomers, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising a compound of this invention, as well as methods relating to the use thereof in a patient in need thereof.
    本发明披露了一种新化合物,其在治疗患者的各种代谢相关疾病方面具有用途。本发明的化合物具有结构(I):其中R1、R2、R3、n、p、q和Ar的定义如本文所述,包括立体异构体和药物可接受的盐。本发明还披露了包括本发明化合物的制药组合物,以及与在需要时使用该化合物的相关方法。
查看更多